Katalog der Deutschen Nationalbibliothek

Springe direkt zu:

Katalog (Beta)

Wissensnetz

Person
Person

Person

Andreas Schneeweiss (1961-)

Arzt

Name

Andreas Schneeweiss

Zeit

1961- (Lebensdaten)

Ort

Heidelberg (Wirkungsort)
Deutschland

Akademischer Grad bzw. Titel

Prof. Dr. med.

Beruf

Arzt (charakteristischer Beruf)

Variante

Andreas Schneeweiß
A. Schneeweiss
A. Schneeweiß

Weitere Angaben

Leiter der Sektion Medikamentöse Gynäkologische Onkologie an der Universitäts-Frauenklinik im Nationalen Centrum für Tumorerkrankungen der Ruprecht-Karls-Universität Heidelberg

Datensatztyp

Person

GND-Nummer

109972554

Datensatz-ID

109972554

Beteiligt an

alle anzeigen

Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry

CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024

Reimbursement in the Context of Precision Oncology Approaches in Metastatic Breast Cancer: Challenges and Experiences

Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry

CDK4/6 inhibition – therapy sequences and the quest to find the best biomarkers – an overview of current programs = CDK4/6-Inhibition: Sequenztherapien und die Suche nach den besten Biomarkern – ein Überblick über die aktuellen Programme

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept

Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept

Relationship of Ki-67 index in biopsies of metastatic breast cancer tissue and circulating tumor cells (CTCs) at the time of biopsy collection

The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial

Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Update breast cancer 2023 part 3: expert opinions of early stage breast cancer therapies

Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)

Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

How previous treatment changes the metabolomic profile in patients with metastatic breast cancer

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT

AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer

Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer

Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer

Update Breast Cancer 2021 Part 4 – Prevention and Early Stages

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022

Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference

Ago recommendations for the surgical therapy of breast cancer: update 2022

AGO Recommendations for the surgical therapy of breast cancer: update 2022

Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients – data from the real-world registry PRAEGNANT = Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial

Trastuzumab-Deruxtecan (Enhertu) : Antikörper-Wirkstoff-Konjugat der neuen Generation zur Behandlung von nicht-operablem oder metastasiertem HER2-positivem Brustkrebs

Update breast cancer 2021 part 4 – prevention and early stages

Update Breast Cancer 2021 Part 4 : Prevention and Early Stages

Update breast cancer 2021 part 5 – advanced breast cancer

Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer

Update breast cancer 2022 part 1 – early stage breast cancer

Update breast cancer 2022 part 1 : early stage breast cancer

Update breast cancer 2022 part 2 – advanced stage breast cancer

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer

Therapiealgorithmen für das Mammakarzinom

Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus : German Expert Opinions on the 17th International St. Gallen Consensus Conference

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021

AGO Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2021

AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer : update 2021

miR-183-5p|+2 suppresses cell cycle by targeting E2F1 in Triple Negative Breast Cancer

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Update breast cancer 2020 part 5: moving therapies from advanced to early breast cancer patients

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Therapieoptionen beim hormonrezeptorpositiven, HER‑2-negativen metastasierten Mammakarzinom

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer

HER2-targeted therapy influences CTC status in metastatic breast cancer
Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

DNB-Portal